G. Erel-Akbaba et al. [145] developed an iRGD (CCRGDKGPDC)-conjugated SLN to deliver siRNA against both epidermal growth factor receptor (EGFR) and PD-L1 for glioblastoma treatment. Here, EGFR is linked to glioblastoma.